Eduardo Bravo

Eduardo Bravo is an accomplished executive with extensive leadership experience in the biotechnology and pharmaceutical sectors. Currently serving as the Chief Executive Officer of Citryll since August 2023, Eduardo also holds chairman positions at Ariceum Therapeutics, Engitix Therapeutics, and Vivet Therapeutics. Previous roles include CEO at Nordic Nanovector ASA and TiGenix, and Eduardo has also served as a board member for Sutura Therapeutics and EBAC, where Eduardo was CEO. Eduardo's educational background includes a Master of Business Administration from INSEAD, earned in 1991.